Drug Approval | April 26, 2022
ZyCoV-D two-dose vaccine receives Emergency Use Approval from DCGI
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
The approval by the DCGI comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO)
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose
The peptide-based vaccine induces a t cell-dependent response
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
The findings support the fact that further extension of nationwide cardiovascular disease (CVD) risk identification programs and prevention strategies to reduce the occurrence of cardiovascular diseases are warranted
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
Subscribe To Our Newsletter & Stay Updated
